About us Contacts Drug interactions: 390 212
Drug search by name

Lorbrena and Velpatasvir and Sofosbuvir Tablets

Determining the interaction of Lorbrena and Velpatasvir and Sofosbuvir Tablets and the possibility of their joint administration.

Check result:
Lorbrena <> Velpatasvir and Sofosbuvir Tablets
Relevance: 10.07.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Using velpatasvir together with lorlatinib is not recommended. Combining these medications may significantly reduce the blood levels of velpatasvir, which may make the medication less effective in treating hepatitis C. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

GENERALLY AVOID: Coadministration with potent or moderate inducers of CYP450 isoenzymes may decrease the plasma concentrations of velpatasvir, which has been shown in vitro to be metabolized by CYP450 2B6, 2C8, and 3A4. The interaction has been studied with efavirenz, a moderate CYP450 2B6 and 3A4 inducer. In 14 healthy volunteers, administration of sofosbuvir-velpatasvir 400 mg -100 mg once daily with efavirenz/emtricitabine/tenofovir disoproxil fumarate 600 mg/200 mg/300 mg once daily decreased mean velpatasvir peak plasma concentration (Cmax), systemic exposure (AUC) and trough plasma concentration (Cmin) by 47%, 53% and 57%, respectively, compared to administration of sofosbuvir-velpatasvir alone. No clinically relevant pharmacokinetic changes were observed for sofosbuvir or its predominant circulating metabolite, GS-331007.

MANAGEMENT: Given the risk of reduced viral susceptibility and resistance development associated with subtherapeutic antiviral drug levels, concomitant use of sofosbuvir-velpatasvir with potent or moderate CYP450 inducers is not recommended.

References
  • Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  • "Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences, Foster City, CA.
Lorbrena

Generic Name: lorlatinib

Brand name: Lorbrena

Synonyms: n.a.

Velpatasvir and Sofosbuvir Tablets

Generic Name: sofosbuvir / velpatasvir

Brand name: Epclusa

Synonyms: Sofosbuvir and velpatasvir, Sofosbuvir and Velpatasvir

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle